Biotech Values

[jbog]

Dew,

Pfizer is now the owner of two promising ALZ drugs that are both in phase III trials.. It'll have control of Elan's bapineuzumab and if you recall it has Dimebon in phase III also.

I think it gained Dimebon from Medivation last year.

Looking at Elan's stock drop 10% today it seems like the street thinks PFE will push Dimebon.